Knight Therapeutics Inc.

TSX:GUD Stock Report

Market Cap: CA$909.1m

Knight Therapeutics Future Growth

Future criteria checks 3/6

Knight Therapeutics is forecast to grow earnings and revenue by 27.5% and 4% per annum respectively. EPS is expected to grow by 26.4% per annum. Return on equity is forecast to be 4.2% in 3 years.

Key information

27.5%

Earnings growth rate

26.36%

EPS growth rate

Pharmaceuticals earnings growth21.1%
Revenue growth rate4.0%
Future return on equity4.20%
Analyst coverage

Good

Last updated06 Aug 2026

Recent future growth updates

Analysis Article • Nov 09

Knight Therapeutics Inc. (TSE:GUD) Just Reported Earnings, And Analysts Cut Their Target Price

Shareholders might have noticed that Knight Therapeutics Inc. ( TSE:GUD ) filed its quarterly result this time last...

Recent updates

Narrative Update • Jul 09

GUD: Higher Discount Rate Will Likely Expose Execution Risk Ahead

Analysts have raised their fair value estimate for Knight Therapeutics from CA$6.15 to CA$9.00, citing recent price target adjustments and renewed coverage that reflect updated views on the discount rate, revenue growth, profit margin, and future P/E assumptions. Analyst Commentary Recent research coverage of Knight Therapeutics highlights a mix of optimism around the revised fair value estimate and pockets of caution around execution and valuation risk.
Narrative Update • Jun 25

GUD: Latin American Drug Launches And Renewed Coverage Will Drive Future Repricing

Analysts have lifted their price target on Knight Therapeutics by CA$1, reflecting updated assumptions for slightly higher revenue growth and profit margins, along with a modestly lower future P/E multiple. Analyst Commentary Recent research coverage on Knight Therapeutics points to a more constructive tone, with bullish analysts emphasizing the refreshed price target and renewed attention on the stock.
Narrative Update • Jun 05

GUD: Latin American Approvals And Buybacks Will Support Future Bullish Repricing

Analysts have revised the fair value estimate for Knight Therapeutics from about CA$12.00 to roughly CA$11.65, reflecting updated assumptions on revenue growth, profit margins and a higher future P/E multiple. Recent Street research also includes higher CA$ price targets and renewed positive coverage.
Narrative Update • May 21

GUD: Latin American Approvals And Buybacks Will Support Future Bullish Repricing

Analysts have raised their fair value estimate for Knight Therapeutics stock from CA$11.00 to CA$12.00, citing recent price target increases and renewed coverage that highlight modest adjustments to growth and margin assumptions, along with a slightly higher future P/E multiple. Analyst Commentary Bullish analysts have recently adjusted their outlook on Knight Therapeutics, pointing to factors that they see as supportive of the higher fair value estimate.
Narrative Update • Apr 25

GUD: Higher 2026 Margins And Buybacks Will Support Bullish Repricing

Analysts have lifted their price target on Knight Therapeutics by CA$0.50, citing updated assumptions around slightly higher revenue growth, profit margins, and a marginally adjusted future P/E. Analyst Commentary Recent research updates point to a modestly more constructive stance on Knight Therapeutics, with bullish analysts reflecting their view through a CA$0.50 lift in the price target.
Narrative Update • Apr 06

GUD: Updated 2026 Guidance And Margin Outlook Will Support Bullish Repricing

Analysts have lifted their price target on Knight Therapeutics by CA$0.50, citing updated assumptions around revenue growth, profit margins and future P/E expectations. Analyst Commentary Recent research points to a more constructive stance on Knight Therapeutics, with bullish analysts adjusting their models to reflect updated views on revenue trajectories, margin sustainability and future P/E assumptions.
Narrative Update • Mar 22

GUD: Higher Earnings Visibility And 2026 Guidance Will Support Bullish Repricing

Analysts have raised their blended price target for Knight Therapeutics to CA$11.00, supported by updated assumptions on discount rate, revenue growth, profit margin and future P/E, as well as a recent CA$0.50 target move from Street research. Analyst Commentary Recent research commentary points to a more constructive tone around Knight Therapeutics, with the CA$0.50 increase in one target contributing to a higher blended price target of CA$11.00.
Analysis Article • May 16

Knight Therapeutics' (TSE:GUD) Solid Profits Have Weak Fundamentals

Knight Therapeutics Inc.'s ( TSE:GUD ) robust earnings report didn't manage to move the market for its stock. Our...
User avatar
New Narrative • May 10

Paladin Acquisition And New Launches Will Expand Market Presence

Acquisitions and expanded partnerships bolster Knight's Canadian and oncology revenue, enhancing stability and growth prospects.
Analysis Article • Mar 18

Knight Therapeutics Inc.'s (TSE:GUD) Popularity With Investors Is Clear

When close to half the companies in the Pharmaceuticals industry in Canada have price-to-sales ratios (or "P/S") below...
Analysis Article • Nov 09

Knight Therapeutics Inc. (TSE:GUD) Just Reported Earnings, And Analysts Cut Their Target Price

Shareholders might have noticed that Knight Therapeutics Inc. ( TSE:GUD ) filed its quarterly result this time last...

Earnings and Revenue Growth Forecasts

TSX:GUD - Analysts future estimates and past financials data (CAD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
3/31/2026510669106N/A
12/31/2025450-53569N/A
9/30/2025414-3336N/A
6/30/20253850-130N/A
3/31/202537311-159N/A
12/31/20243714536N/A
9/30/2024349-312153N/A
6/30/2024338-213263N/A
3/31/2024332-174963N/A
12/31/2023328-172636N/A
9/30/2023336-81025N/A
6/30/2023326-16621N/A
3/31/2023312-15336N/A
12/31/2022294-301945N/A
9/30/2022270-232143N/A
6/30/2022271-331842N/A
3/31/2022261-7-18340N/A
12/31/202124316-18045N/A
9/30/202124032-18144N/A
6/30/202121259-19531N/A
3/31/202120047726N/A
12/31/202020042-33-12N/A
9/30/202018227-27-9N/A
6/30/20201406-16-2N/A
3/31/2020908N/A-7N/A
12/31/20194715N/A5N/A
9/30/20191421N/A0N/A
6/30/20191337N/A-24N/A
3/31/20191222N/A-22N/A
12/31/20181324N/A-6N/A
9/30/20181131N/A-4N/A
6/30/20181022N/A27N/A
3/31/20181018N/A26N/A
12/31/2017917N/A23N/A
9/30/2017818N/A21N/A
6/30/2017820N/A15N/A
3/31/2017724N/A14N/A
12/31/2016619N/A15N/A
9/30/2016416N/A24N/A
6/30/2016317N/A19N/A
3/31/2016221N/A15N/A
12/31/2015134N/A10N/A
9/30/20151154N/A-2N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: GUD's forecast earnings growth (27.5% per year) is above the savings rate (3.1%).

Earnings vs Market: GUD's earnings (27.5% per year) are forecast to grow faster than the Canadian market (11.3% per year).

High Growth Earnings: GUD's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: GUD's revenue (4% per year) is forecast to grow slower than the Canadian market (4.1% per year).

High Growth Revenue: GUD's revenue (4% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: GUD's Return on Equity is forecast to be low in 3 years time (4.2%).

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/08/06 23:49
End of Day Share Price 2026/08/06 00:00
Earnings2026/06/30
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Knight Therapeutics Inc. is covered by 12 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Tania Armstrong-WhitworthATB Cormark Historical (Cormark Securities)
David KideckelBeacon Securities Limited
David MartinBloom Burton & Co.